I had invested but ultimately sold my shares after realizing the low valuation appears to be due to concerns over how long XINITITY revenues will be likely to continue for. Pfizer has a genetic treatment for Hemophilia B that is currently in phase 3 trials. The results have been very positive so far and their treatment would likely dominate the market since one dose lasts for 1yr+.
News 
Market Data 
Discover 
